| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 10, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 10, 2012-- Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2012 on Tuesday, February 21,...
-
Feb 8, 2012New Clinical Data Presented for First Time at Medical Meetings in U.S. and Europe Show Durable Vessel Patency in Treating Atherosclerotic Lesions of Superficial Femoral Artery
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 8, 2012-- Consistent with its commitment to developing better treatments for peripheral arterial disease (PAD), Medtronic Inc. (NYSE:MDT) today announced the...
-
Feb 1, 2012IMPROVE HF Bridge Study Will Examine Specific Gaps in Implementation of Guideline-Recommended Treatment in Heart Failure Patients Post-Hospital Discharge
MINNEAPOLIS--(BUSINESS WIRE)--Feb. 1, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the initiation and first patient enrollment in a clinical study that will evaluate gaps in the...
-
Jan 30, 2012New System Builds On Sprint Quattro® Lead, Adding to the Company’s Portfolio of Innovative Technologies Proven to Treat Heart Rhythm Disorders
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 30, 2012-- Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval and launch of the DF4 High-Voltage Connector System, a...
-
Jan 30, 2012Multicenter Experience Demonstrates Surgical Approach, with Recent CE Mark, is a Feasible Alternative for Transcatheter Aortic Valve Implantation
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 30, 2012-- Medtronic, Inc. (NYSE: MDT) today issued a statement on the results of two studies evaluating the use of the Medtronic CoreValve® System delivered...
-
Jan 30, 2012Multicenter Experience Demonstrates Surgical Approach, with Recent CE Mark, is a Feasible Alternative for Transcatheter Aortic Valve Implantation
MINNEAPOLIS, Jan 30, 2012 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today issued a statement on the results of two studies evaluating the use of the Medtronic CoreValve(R) System delivered...
-
Jan 27, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 27, 2012-- Medtronic, Inc. (NYSE: MDT) today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC – a company...
-
Jan 24, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 24, 2012-- Medtronic, Inc. (NYSE: MDT) today announced the first patient was enrolled in the FIRE AND ICE clinical trial, which is a prospective, randomized,...
-
Jan 24, 2012CoreValve U.S. Trial to Continue Enrolling Patients in High Risk Study, and Will Maintain Therapy Access to Extreme Risk Patients via Continued Access Phase of Trial
MINNEAPOLIS, Jan 24, 2012 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced it has completed patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The...
-
Jan 23, 2012
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 23, 2012-- Medtronic, Inc. (NYSE:MDT) announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for the Aquamantys® SBS...